Autobahn's ASP3652 Acquisition: A Platform Bet With No Clinical Proof-of-Concept Yet

Autobahn Acquires Clinical-Stage FAAH Inhibitor from Astellas

Autobahn Therapeutics announced the acquisition of global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor, from Astellas Pharma Inc. This strategic move enhances Autobahn's brain-targeting chemistry platform, which utilizes FAAH-mediated prodrug conversion to facilitate small molecule delivery across the blood-brain barrier. ASP3652, previously evaluated in ten clinical studies involving over 200 individuals with a favorable safety profile, is intended to improve selective brain delivery of Autobahn's compounds and will be developed in combination with pipeline programs, including proprietary selective thyroid hormone receptor beta (TRβ) agonists for multiple sclerosis (MS).

• Autobahn Therapeutics has acquired global rights to ASP3652, a clinical-stage peripherally restricted FAAH inhibitor from Astellas Pharma Inc. This acquisition is a strategic move to bolster Autobahn's proprietary brain-targeting chemistry platform, which leverages FAAH-mediated prodrug conversion to enhance the delivery of small molecules across the blood-brain barrier for central nervous system (CNS) disorders.
• ASP3652's mechanism involves peripheral FAAH inhibition, which is designed to improve the selective brain delivery of Autobahn's prodrugs by limiting peripheral hydrolysis, thereby enhancing the therapeutic index. This synergy is particularly relevant for combination therapies, such as with Autobahn’s selective thyroid hormone receptor beta (TRβ) agonists, which are being developed for conditions like multiple sclerosis (MS).
• ASP3652 has demonstrated a favorable safety profile across ten prior clinical studies involving over 200 unique persons. The drug also showed sustained elevation of the endogenous substrate anandamide for up to 24 hours post-dose, suggesting potential for once-daily dosing. Autobahn plans to accelerate its development timeline, particularly for MS, by combining ASP3652 with its novel TRβ prodrugs, aiming for a first-in-class therapeutic approach.

ASP3652: A Clinical-Stage FAAH Inhibitor with Favorable Safety

ASP3652, a peripherally acting inhibitor of fatty acid amide hydrolase (FAAH), has been evaluated across multiple Phase I and Phase II studies in healthy volunteers and patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Across this clinical program, single and multiple doses were consistently well tolerated, with adverse event profiles comparable to placebo.

• Phase I — Japanese healthy volunteers (single and multiple doses): ASP3652 was administered at single doses of 30–900 mg and multiple doses of 100 and 300 mg BID. The incidence of adverse events after multiple doses ranged from 44.4% to 66.7% and was similar across all treatment groups, including the placebo group. Single and multiple doses were well tolerated.

• CNS penetration and supratherapeutic dose safety: In a dedicated CNS transfer study, AUC and C of ASP3652 in cerebrospinal fluid were approximately 0.2% and 0.06% of the corresponding plasma values after multiple doses of 300 mg BID, confirming low CNS penetration. In a crossover study evaluating single ascending doses of 600–1800 mg, the incidence of adverse events was similar across all treatment groups including placebo, and there was no evidence of CNS-related side effects.

• Phase II — IC/BPS (ASP3652 50, 150, or 300 mg twice daily for 12 weeks): In 287 randomized adult female patients, adverse event incidence was low and similar between study groups across all dose levels. ASP3652 was safe and well tolerated throughout the 12-week treatment period, though it did not demonstrate efficacy versus placebo on the primary endpoint of Mean Daily Pain.

• Pharmacodynamic safety signal — FAAH inhibition and endocannabinoid elevation: Across studies, FAAH activity was inhibited in a dose-dependent manner, and plasma levels of anandamide, oleoylethanolamide, and palmitoylethanolamide increased in all dose groups after single and multiple doses. These pharmacodynamic effects were not associated with adverse clinical findings, consistent with ASP3652's peripheral mechanism of action.

Enhancing Brain Delivery: ASP3652's Role in Combination MS Therapies

Several combination therapy strategies have been evaluated in multiple sclerosis trials, with approaches spanning established disease-modifying therapies, corticosteroids, and emerging targeted agents.

• Monthly pulsed methylprednisolone as add-on therapy: A multicentre, single-blind, prospective trial assessed intravenous methylprednisolone (1 g IV) once monthly for 12 months added to either subcutaneous interferon beta or glatiramer acetate in 103 relapsing-remitting MS patients. The decrease in absolute annualized relapse rate was 0.69, 72 patients were relapse-free at year's end, and health-related quality of life measured using the MS Quality of Life scale improved significantly. The combinations were reported as safe and well tolerated.

• Interferon β-1a plus glatiramer acetate (CombiRx): A double-blind, randomized, controlled study of 1,008 participants compared combination interferon β-1a (30 μg intramuscularly weekly) and glatiramer acetate (20 mg daily) against either agent alone over 3 years. Combination therapy was not superior to glatiramer acetate alone in reducing relapse risk or confirmed Expanded Disability Status Scale progression, though it was superior to either agent alone in reducing new lesion activity and accumulation of total lesion volumes. In a post hoc analysis, combination therapy resulted in a higher proportion of participants attaining disease activity-free status compared to either single arm, driven by MRI results.

• Achillea millefolium aqueous extract as add-on therapy: A triple-blind, randomized, placebo-controlled parallel-group trial in 75 MS patients evaluated A. millefolium at 250 mg/day and 500 mg/day for one year added to standard care. Both doses decreased the annual relapse rate; the 500 mg group showed a significant decrease in mean lesion volume change. Add-on therapy also increased time to first relapse, improved the MSFC z-score, decreased EDSS score, and improved performance on word-pair learning, PASAT, and WCST.

• BTK inhibitors as a novel combination-compatible class: Bruton's tyrosine kinase (BTK) inhibitors represent an emerging oral therapeutic approach targeting both peripheral adaptive and CNS-compartmentalized innate immune pathways. Tolebrutinib has demonstrated efficacy against disability progression in non-relapsing secondary progressive MS, while fenebrutinib has shown promise in both relapsing and primary progressive MS in Phase 2 and Phase 3 trials. Their capacity to cross the blood-brain barrier at biologically relevant concentrations distinguishes them mechanistically from existing agents, though adverse events include elevated liver enzymes, which can reach life-threatening levels.

Addressing the Critical Unmet Need for Remyelination in MS

The knowledge base does not have sufficient information to answer this question.

Autobahn's FAAH Strategy: A New Path for CNS Therapies

Autobahn Therapeutics' recent acquisition of ASP3652 marks a pivotal moment in the pursuit of effective central nervous system (CNS) therapies. This move is not merely about adding an asset; it's about fortifying a sophisticated, innovative strategy to overcome one of the most formidable challenges in drug development: the blood-brain barrier (BBB). Autobahn's platform leverages the fatty acid amide hydrolase (FAAH) enzyme, which is notably enriched in the CNS, to convert peripherally restricted prodrugs into active therapeutic agents directly within the brain.

The integration of ASP3652, a peripherally restricted FAAH inhibitor with a well-documented safety and tolerability profile from extensive clinical studies, provides a crucial de-risking element for this platform. It offers a clinically validated component that can be developed in combination with Autobahn's proprietary pipeline. The immediate and compelling application lies in multiple sclerosis (MS), where Autobahn is developing selective thyroid hormone receptor beta (TRβ) agonists. Research indicates that CNS-selective TRβ agonists hold significant promise for stimulating myelin repair and protecting against neurodegeneration, addressing a critical unmet need in MS without the systemic adverse effects associated with non-selective thyroid hormone administration.

However, this innovative approach is not without its considerations. While the concept is sound, the precise efficiency and consistency of FAAH-mediated prodrug conversion of Autobahn's specific compounds to therapeutic levels within the human brain will require robust clinical validation. Furthermore, although ASP3652 has shown a favorable safety profile, the long-term implications of sustained peripheral FAAH inhibition, especially in chronic combination therapy, warrant careful monitoring. The inherent complexities of developing combination therapies, including dose optimization and potential drug-drug interactions, will also be a key focus. Nevertheless, this strategic acquisition positions Autobahn to potentially accelerate the delivery of truly brain-penetrant therapies, offering a new paradigm for targeted CNS action and holding significant promise for patients suffering from neurological disorders.